Immuron Limited

IMC

AU000000IMC7

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 11:40:13 28/06/2024 am IST			5-day change	1st Jan Change
0.088 ^AUD	0.00%		+4.76%	+14.29%

05/06	Immuron Limited Appoints Jeannette Joughin as Director	CI
31/05	Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director	CI

Immuron Limited Announces Unaudited Sales Results for the First Half Year Ended December 31, 2019

January 28, 2020 at 03:43 am IST

Immuron Limited announced unaudited sales results for the first half year ended December 31, 2019. The company experienced gross sales growth in the US, Canada and Australia throughout the first half Of fiscal year 2020, with global sales reaching AUD 1.68 million during the 6-month period.

Latest news about Immuron Limited

Immuron Limited Appoints Jeannette Joughin as Director	05/06	CI
Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director	31/05	CI
Immuron Limited Announces Stephen Anastasiou Has Resigns as Non-Executive Director	03/05	CI
Immuron Limited Provides Sales Results for the Quarter and Year to Date Ended March 2024	10/04	CI
Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%	10/04	MT
Sector Update: Health Care Stocks Gain Late Afternoon	08/03	MT
Sector Update: Health Care	08/03	MT
Top Midday Gainers	08/03	MT
Top Premarket Gainers	07/03	MT
Immuron Moving Anti-Diarrhea Drug to Phase Three Trials	07/03	MT
Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US	07/03	CI
Immuron Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02	CI
Immuron Limited Reports Unaudited Net Sales Results for the Year to Date Ended January 2024	13/02	CI
Immuron's Travelan Immune Supplement Registers AU$2.7 Million Sales in YTD January	13/02	MT
Immuron Limited Reports Sales Results for First Half 2024	16/01	CI
Immuron Posts Record Travelan Sales in Fiscal H1	16/01	MT
Immuron Limited Clinical Trials Update	22/12	CI
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study	04/12	CI
Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences	18/23/18	CI
Immuron Limited Reports Sales Results for the First Quarter of 2024	11/23/11	CI
Immuron Reports Big Jump in Fiscal Q1 Travelan Sales	11/23/11	MT
Immuron Sees Nearly 8000% Boost in August Sales of Gastrointestinal Drug	14/23/14	MT
Immuron Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
Immuron Limited Receives TGA GMP Clearance	09/23/09	CI
Immuron Secures Clearance for Packaging of Immunotherapy Product; Shares Surge 27%	09/23/09	MT

Chart Immuron Limited

Duration

Period

More charts

Company Profile

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelerâs diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.

Sector

Pharmaceuticals

Calendar

30/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
IMMURON LIMITED	+14.29%	13.33M
CSL LIMITED	+2.99%	94.76B
SAMSUNG BIOLOGICS CO.,LTD.	-4.34%	37.58B
BIOGEN INC.	-11.23%	33.3B
UCB	+75.79%	27.92B
BIOMARIN PHARMACEUTICAL INC.	-13.79%	15.85B
INCYTE CORPORATION	-3.63%	13.79B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.31%	11.51B
ALTEOGEN INC.	+184.77%	10.9B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.13%	9.27B